Alimentary pharmacology & therapeutics
-
Aliment. Pharmacol. Ther. · Apr 2011
ReviewReview article: proton pump inhibitors with clopidogrel--evidence for and against a clinically-important interaction.
The treatment of acute coronary syndromes involves a combination of antiplatelet therapies. Proton pump inhibitors are frequently recommended for patients receiving clopidogrel in addition to aspirin, to minimise the risk of bleeding. Several studies have shown that proton pump inhibitors can affect the platelet inhibitory effects of clopidogrel. However, the data on whether this has an effect on clinical outcomes are conflicting and a definitive answer is still awaited. ⋯ Proton pump inhibitors offer clear protection and the concern over clinically relevant interactions with clopidogrel is biologically plausible, but not yet proven.
-
Aliment. Pharmacol. Ther. · Apr 2011
ReviewSystematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease.
Polycystic ovary syndrome (PCOS) is a common disorder for women of child-bearing age and is associated with metabolic syndrome (MS). ⋯ Non-alcoholic fatty liver disease is considered as the hepatic manifestation of metabolic syndrome. Similarly, it seems appropriate to consider polycystic ovary syndrome as the ovarian manifestation of metabolic syndrome. Both these conditions can co-exist and may respond to similar therapeutic strategies.